9th July 2026
Read More
Welcome
This is MU-JHU!
We are an indigenous medical research and care organization in existence since 1988, located on Upper Mulago Hill in Kampala. MU-JHU is a key player in contributor to new knowledge in HIV prevention, care, and treatment, community HIV programs as well as non-HIV research, and training. We envision a Uganda where all women, children, adolescents, and their families enjoy full health and wellbeing. Our mission is to be a Centre of excellence in health research, and care for women, adolescents, children, and their families.
Our Mission
To undertake health research, provide health-services and conduct training; focusing on HIV, prevalent and emerging conditions affecting the well-being of women, children, youth and families.
Our Research Domains
- Perinatal HIV/TB Prevention and Care
- Pediatric and Infant Health
- Growth, Neurodevelopment and Bone Health
- Bacterial Infections and Vaccine Development
- Blood Safety and Infection Prevention
Clinical Trial Phases
- Phase I (Safety & Dosage)
- Phase II (Effectiveness & Side Effects)
- Phase III (Efficacy & Comparison)
- Phase IV (Long-term/Post-marketing)
- Adaptive Trials
See Clinical Research Regulations in Uganda
Announcements
New Studies
Our latest protocols and clinical trials
- An open-label randomised controlled trial comparing novel combination and currently used antibiotic regimens for the empiric treatment of neonatal sepsis with a run-in confirmatory pharmacokinetic phase: NeoSep1. Principal Investigator – Dr. Maxensia Owor
- IMPAACT 2024: Phase I/II Dose Finding, Safety and Tolerability Study of Daily Rifapentine Combined with Isoniazid (1HP) for Tuberculosis Prevention in Children Less Than 13 Years of Age with and without HIV. Principal Investigator – Dr. Eric Wobudeya
- A phase 2, Randomized, Adaptive, Dose-Ranging, Open-Label Trial of Novel Regimens for the Treatment of Pulmonary Tuberculosis (RAD-TB). Principal Investigator – Dr. Deo Wabwire
- A Phase 3, Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy and Safety of MK-8527 Oral Once-Monthly as HIV-1 Preexposure Prophylaxis in Women. Principal Investigator – Dr. Flavia Matovu Kiweewa
Grant Awards
2025 IMPAACT Early Career Investigator Award
Dr. Denis Kimbugwe
2025 IMPAACT Early Career Investigator Award
Dr. Grace Miriam Ahimbisibwe
2025 IMPRINT Visiting Fellowship
Dr. Gerald Businge
2025 IMPRINT Visiting Fellowship
Dr. Robert Mboizi
New Articles
Our Work
Our Partners
© 2022 MU-JHU Research Collaboration. All rights reserved